<DOC>
	<DOCNO>NCT00358215</DOCNO>
	<brief_summary>The purpose study determine efficacy treatment anemia darbepoetin alfa compare placebo composite time death cause first hospital admission worsen heart failure patient symptomatic leave ventricular systolic dysfunction anemia .</brief_summary>
	<brief_title>RED-HF™ Trial - Reduction Events With Darbepoetin Alfa Heart Failure Trial</brief_title>
	<detailed_description>Several epidemiological study demonstrate association HF anemia correlation increase risk mortality hospitalization low hemoglobin patient HF . Earlier single-center interventional study suggest meaningful clinical benefit may achieve raise hemoglobin concentration patient symptomatic HF anemia . Data Amgen 's complete phase 2 multi-center study support hypothesis show darbepoetin alfa well tolerated patient symptomatic leave ventricular systolic dysfunction anemia effectively raise hemoglobin . The pivotal phase 3 Study 20050222 RED-HF Trial evaluate effect treatment darbepoetin alfa composite risk all-cause mortality hospitalization worsen HF patient symptomatic leave ventricular systolic dysfunction anemia . This study also evaluate effect darbepoetin alfa treatment all-cause death , cardiovascular death hospitalization worsen HF , patient-reported quality-of-life outcome .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Heart failure least 3 month duration New York Heart Association ( NYHA ) class II , III , IV hemoglobin 9.0 g/dL 12.0 g/dL leave ventricular ejection fraction equal le 40 % Transferrin saturation ( Tsat ) &lt; 15 % Blood pressure &gt; 160/100 mm Hg Heart failure primarily due valvular heart disease clinically significant valvular heart disease might lead surgical correction within 12 month randomization Recipient major organ transplant receive renal replacement therapy Serum creatinine &gt; 3.0 mg/dL ( &gt; 265 µmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Survival study</keyword>
	<keyword>morbidity mortality</keyword>
	<keyword>heart failure hospitalization</keyword>
	<keyword>all-cause death</keyword>
	<keyword>patient-reported outcome</keyword>
	<keyword>Kansas City Cardiomyopathy questionnaire</keyword>
	<keyword>anemia treatment</keyword>
</DOC>